Detalhe da pesquisa
1.
CDK4/6 inhibition triggers anti-tumour immunity.
Nature
; 548(7668): 471-475, 2017 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28813415
2.
Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.
FASEB J
; 33(2): 1644-1657, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30161001
3.
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Nature
; 486(7403): 353-60, 2012 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22722193
4.
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Breast Cancer Res
; 19(1): 123, 2017 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29162134
5.
Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.
Breast Cancer Res Treat
; 165(2): 355-364, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28612227
6.
Genome remodelling in a basal-like breast cancer metastasis and xenograft.
Nature
; 464(7291): 999-1005, 2010 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20393555
7.
Evaluation of copanlisib in combination with eribulin in triple negative breast cancer patient-derived xenograft models.
Cancer Res Commun
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38717161
8.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 10(3): 362-371, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38236590
9.
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN).
NPJ Breast Cancer
; 9(1): 1, 2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36609389
10.
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
Cancer Res
; 83(24): 4161-4178, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38098449
11.
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Cancer Discov
; 12(11): 2586-2605, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001024
12.
Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1.
Cell Rep
; 34(7): 108749, 2021 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33596420
13.
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
Nat Commun
; 12(1): 5086, 2021 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34429404
14.
Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells.
J Exp Med
; 198(10): 1595-608, 2003 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-14623913
15.
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Breast Cancer Res Treat
; 119(2): 379-90, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19844788
16.
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
J Natl Cancer Inst
; 112(7): 737-746, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31665365
17.
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.
Cancers (Basel)
; 12(12)2020 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33371187
18.
Microscaled proteogenomic methods for precision oncology.
Nat Commun
; 11(1): 532, 2020 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31988290
19.
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.
Clin Cancer Res
; 24(19): 4887-4899, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29793947
20.
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.
Cell Rep
; 24(6): 1434-1444.e7, 2018 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30089255